SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-007132
Filing Date
2016-08-02
Accepted
2016-08-02 16:39:36
Documents
40
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20160630x10q.htm 10-Q 980005
2 EX-31.1 nvls-20160630ex3112a4bc1.htm EX-31.1 18297
3 EX-31.2 nvls-20160630ex312d25074.htm EX-31.2 18303
4 EX-32.1 nvls-20160630ex3213b35cf.htm EX-32.1 8812
  Complete submission text file 0001558370-16-007132.txt   3053320

Data Files

Seq Description Document Type Size
5 EX-101.INS nvls-20160630.xml EX-101.INS 582358
6 EX-101.SCH nvls-20160630.xsd EX-101.SCH 17057
7 EX-101.CAL nvls-20160630_cal.xml EX-101.CAL 25686
8 EX-101.DEF nvls-20160630_def.xml EX-101.DEF 53648
9 EX-101.LAB nvls-20160630_lab.xml EX-101.LAB 190548
10 EX-101.PRE nvls-20160630_pre.xml EX-101.PRE 131620
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 161801027
SIC: 2834 Pharmaceutical Preparations